By: IPP Bureau
Last updated : January 30, 2026 7:20 pm
EYRA features intuitive software, automation readiness, and the ability to detect dozens of analytes simultaneously with minimal hands-on time
Mabtech, a global leader in advanced immunoassays, and Sai Life Sciences, a top integrated CRDMO, have announced a strategic partnership that positions Sai’s Boston laboratory as a co-marketed US hub for the Mabtech EYRA platform.
The collaboration will bring cutting-edge immunology assay services—including high-sensitivity multiplex cytokine and phenotyping workflows—directly to biopharma and biotech companies through EYRA at Sai’s Boston discovery site. The move aims to accelerate next-generation immune profiling in areas such as immuno-oncology, vaccines, inflammation, and cellular therapy.
“We’re excited to see EYRA placed at Sai Life Sciences and integrated into their US discovery operations,” said Kimberlee Parent, Head of US Operations at Mabtech.
“This installation enables Sai to offer EYRA’s powerful, no-flow multiplex immunology readouts to their broad customer base, expanding access to high-quality, reproducible immune profiling. Together, Mabtech’s assay expertise and Sai’s strong discovery and translational capabilities create a compelling new service offering for researchers.”
EYRA features intuitive software, automation readiness, and the ability to detect dozens of analytes simultaneously with minimal hands-on time. Developed through a long-term R&D collaboration, the platform overcomes key limitations of traditional flow- and plate-based systems, delivering streamlined and scalable immune profiling workflows.
“For our discovery clients, the ability to generate reliable, decision-enabling data early is critical,” said Maneesh Pingle, Head of Discovery Services at Sai Life Sciences.
“By establishing our Boston site as a US execution hub for EYRA-enabled immunology workflows, we are strengthening Sai’s capability to support complex programs in immunology and immuno-oncology. This collaboration with Mabtech allows us to integrate advanced immune profiling seamlessly into broader discovery and translational strategies—helping teams move from biological hypothesis to confident development decisions faster.”
The partnership will feature joint delivery of EYRA-based immunology panels and custom assays, co-branded demonstrations and pilot programs at Sai Boston, shared thought leadership, and integrated business development support spanning discovery to translational research.